ClinicalTrials.gg
CompletedNCT03847428EMERALD-2Updated Oct 8, 2026

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

A Phase 3 interventional study of Durvalumab and Bevacizumab in Hepatocellular Carcinoma, sponsored by AstraZeneca. Completed at 217 sites in 24 countries. Open to participants aged 18 Years to 150 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Oct 8, 2026Now CompletedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
908
Allocation
Randomized
Ages
18 Years to 150 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing durvalumab in Carcinoma, Hepatocellular — 22 open to participants now, 32 under way, 4 of them phase 3. durvalumab · Carcinoma, Hepatocellular.

Enrollment
2nd of 42
908 · median 37
Started
2019
with 1 other
Phase 3
5 of 42
1 open now
Registered
7th of 42
by date
Lead sponsor
7 of 42
AstraZeneca

Among the 42 studies testing durvalumab in Carcinoma, Hepatocellular, this one is the 2nd largest by enrollment, is one of 2 that started in 2019, is one of 5 in phase 3, and was the 7th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

22 of the 42 studies testing durvalumab in Carcinoma, Hepatocellular are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 150 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing durvalumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.

Read the detailed description

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab monotherapy or placebo as adjuvant therapy. This study will be conducted in patients with HCC who are at high risk of recurrence after curative hepatic resection or ablation.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Early stage HCC
  • Durvalumab
  • Bevacizumab
  • Liver Cancer
04

Who can participate

Ages eligible
18 Years to 150 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically or cytologically (or radiologically for patients undergoing curative ablation), newly diagnosed, confirmed HCC and successfully completed curative therapy (resection or ablation)
  • Imaging to confirm disease-free status within 28 days prior to randomization
  • 0-1 at enrolment
  • score of 5 or 6
  • Adequate organ and marrow function.

Exclusion criteria

Exclusion Criteria:

  • Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
  • Evidence of , macrovascular invasion or co-existing malignant disease on baseline imaging
  • History of hepatic encephalopathy within 12 months prior to randomization
  • Evidence, by Investigator assessment, of varices at risk of bleeding on upper endoscopy or contrast-enhanced cross-sectional imaging
  • Patients with Vp1 to Vp4 portal vein thrombosis on baseline imaging are excluded
  • Active co-infection with and HDV.
  • Receipt of prior systemic anticancer therapy for HCC
  • Those on a waiting list for liver transplantation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
908 participants (actual)

Study arms

  • Experimental
    Arm A

    Durvalumab 1120 mg (Q3W) + bevacizumab 15 mg/kg (Q3W)

    Drug: Durvalumab · Drug: Bevacizumab

  • Experimental
    Arm B

    Durvalumab 1120 mg (Q3W) + bevacizumab placebo (Q3W)

    Drug: Durvalumab · Other: Placebo

  • Placebo comparator
    Arm C

    Durvalumab placebo (Q3W) + bevacizumab placebo (Q3W)

    Other: Placebo

Interventions

  • Durvalumab IV (intravenous)

    Also known as: IMFINZI

  • Bevacizumab IV (intravenous)

    Also known as: AVASTIN

  • OtherPlacebo

    Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous) or Dextrose for Durvalumab masking

06

What researchers measure

Primary outcomes

  1. Recurrence-free survival (RFS) for Arm A vs Arm C

    RFS (per RECIST 1.1 criteria as assessed by BICR) will be defined as the time from the date of randomization until the date of the first objective radiologic recurrence or death due to any cause, whichever occurs first.

    Time frame: Up to 49 months after first patient randomized

Secondary outcomes

  1. Recurrence-free survival (RFS) Arm B vs Arm C

    RFS (per RECIST 1.1 criteria as assessed by BICR) will be defined as the time from the date of randomization until the date of the first objective radiologic recurrence or death due to any cause, whichever occurs first.

    Time frame: Up to 49 months after first patient randomized

  2. Overall Survival (OS) for Arm A vs Arm C and Arm B vs Arm C

    OS is defined as the time from the date of randomization until death due to any cause

    Time frame: No timeframe

  3. Recurrence-free survival at 24 months (RFS24) and 36 months (RFS36) for Arm A vs Arm C and Arm B vs Arm C

    Proportion of RFS at 24 months and at 36 months

    Time frame: At 24 and at 36 months

  4. Time to recurrence (TTR) for Arm A vs Arm C and Arm B vs Arm C

    TTR is defined as the time from the date of randomization until the date of disease recurrence

    Time frame: Up to 49 months after first patient randomized

  5. Time from randomization to recurrence/progression on next therapy (RFS2/PFS2) for Arm A vs Arm C and Arm B vs Arm C

    Time from randomization to recurrence/progression on next therapy (RFS2/PFS2)

    Time frame: Up to 49 months after first patient randomized

07

Study locations

217 sites
  • Research Site
    Birmingham, Alabama 35233, United States
  • Research Site
    Mobile, Alabama 36604, United States
  • Research Site
    Phoenix, Arizona 85054, United States
  • Research Site
    Costa Mesa, California 92627, United States
  • Research Site
    La Jolla, California 92093-0698, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Sacramento, California 95817, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Miami, Florida 33176, United States
  • Research Site
    Tampa, Florida 33606, United States
  • Research Site
    Honolulu, Hawaii 96819, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Westwood, Kansas 66205, United States
  • Research Site
    Louisville, Kentucky 40206, United States
  • Research Site
    Shreveport, Louisiana 71103, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Omaha, Nebraska 68198, United States
  • Research Site
    New Brunswick, New Jersey 08903, United States
  • Research Site
    Albuquerque, New Mexico 87109, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Stony Brook, New York 11794, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Winston-Salem, North Carolina 27157, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Knoxville, Tennessee 37916, United States
  • Research Site
    Memphis, Tennessee 38104, United States
  • Research Site
    Dallas, Texas 75216, United States
  • Research Site
    Madison, Wisconsin 53715, United States
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    Melbourne, 3004, Australia
  • Research Site
    Nedlands, 6009, Australia
  • Research Site
    Westmead, 2145, Australia
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Linz, 4010, Austria
  • Research Site
    Sankt Pölten, 3100, Austria
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Porto Alegre, 90020-090, Brazil
  • Research Site
    Porto Alegre, 90035-003, Brazil
  • Research Site
    Rio de Janeiro, 20231-050, Brazil
  • Research Site
    Santa Maria, 97015-450, Brazil
  • Research Site
    Santo André, 09060-870, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    Vitória, 29043-272, Brazil
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
  • Research Site
    Kingston, Ontario K7L 2V7, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Québec, Quebec G1R 2J6, Canada
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Fuzhou, 350005, China
  • Research Site
    Guangzhou, 510000, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310016, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150049, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Hohhot, 010010, China
  • Research Site
    Nanjing, 2100008, China
  • Research Site
    Nanjing, 210002, China
  • Research Site
    Ningbo, 315100, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 201114, China
  • Research Site
    Shanghai, 201318, China
  • Research Site
    Tianjin, 300170, China
  • Research Site
    Ürümqi, 830000, China
  • Research Site
    Wuhan, 430079, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Zhengzhou, 450052, China
  • Research Site
    Alexandria, 21131, Egypt
  • Research Site
    Asyut, 71511, Egypt
  • Research Site
    Cairo, 11451, Egypt
  • Research Site
    Cairo, 11588, Egypt
  • Research Site
    Cairo, 11796, Egypt
  • Research Site
    Dakahlia, 35516, Egypt
  • Research Site
    New Cairo, 11566, Egypt
  • Research Site
    Shebeen El Kom, 32511, Egypt
  • Research Site
    Amiens, 88054, France
  • Research Site
    Angers, 49933, France
  • Research Site
    Besançon, 25000, France
  • Research Site
    Clichy, 92110, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Nantes, 44093, France
  • Research Site
    Nice, 06200, France
  • Research Site
    Paris, 75571, France
  • Research Site
    Pessac, 33604, France

Showing the first 100 of 217 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in May 2026, 84 months.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 84 months is above that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

Completion moved once since we started tracking on Sep 25, 2026: May 2027 → Jul 2026, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2019
First posted
Feb 20, 2019
StartActual
Apr 29, 2019
Primary completionActual
May 15, 2026
CompletionActual
Jul 27, 2026was May 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 8, 2026
Study completion
May 31, 2027→Jul 27, 2026 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Active, not recruiting→Completed
    Study completion May 31, 2027→Jul 27, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03847428
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 20, 2019
Start date
Apr 29, 2019
Primary completion
May 15, 2026
Completion
Jul 27, 2026
Last update
Oct 8, 2026

Study contacts

Jia Fan, PhD
principal investigator · Liver Cancer Institute Zhongshan Hospital, Fudan University
Jennifer Knox, MD
principal investigator · Solid Tumor Medical Oncology Princess Margaret Cancer Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Bevacizumab

Start the discussion